Axonova

Executive Summary

Axonova is a French biotechnology company founded in 2016, operating a dual business model that combines contract bio-analysis and research services with internal drug discovery for neurodegenerative disorders. Leveraging its operational presence in Mauritius, the company utilizes regional biodiversity to identify novel therapeutics. Its service business provides recurring revenue while the pipeline focuses on early-stage candidates for conditions such as Alzheimer's and Parkinson's disease. Although the company remains private and early-stage, its dual approach mitigates risk and provides a foundation for growth. Key upcoming catalysts include potential partnership announcements, progress in preclinical studies, and a planned Series A funding round to advance its most promising candidates toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic research collaboration for neurodegenerative drug discovery60% success
• Q2 2027Completion of Series A financing round to fund pipeline advancement70% success
• TBDLead candidate enters preclinical development for Alzheimer's disease50% success